European CEO Magazine has named Alvogen’s Robert Wessman as the Best CEO in the Pharmaceuticals Industry.
The award is recognition of Alvogen’s extraordinary growth and success in a challenging market. The US generic drug market, in particular, is going through a period of transformation, which is forcing the largest players to withstand unprecedented pressure on their base portfolios.Top pharma executives are having to think on their feet and find new ways of remaining competitive in the new climate.
Thanks to a well-targeted portfolio for the US and Central and Eastern (CEE) markets, Alvogen has been able to make a mark in the industry. Within just eight years, the company has built a solid commercial presence in 35 countries around the world and established strong platforms in emerging markets in the CEE and Asia-Pacific regions.
Last year, Alvogen posted global revenues exceeding US$1bn for the first time, while sister company, Alvotech, is in a great position to take advantage of the market shift towards biosimilars.
Alvogen’s trajectory has prompted the business community to sit up and take note. Wessman’s strategies have been analyzed in extensive detail in two cases by the Harvard Business Review. The European CEO award acknowledges Alvogen’s sustained progress in the industry.
Wessman said: “It’s an honour to be named European CEO Magazine’s Best CEO in the Pharmaceuticals Industry. The award is for everybody at Alvogen. The team’s hard work and unique market insights have been pivotal in the company establishing itself as a leader in growth pharmaceuticals.”